Merck and IDEAYA face Oct. 10 FDA decisions while Johnson & Johnson earnings test pipeline momentum

MRK looks like the wrong kind of binary into its Oct. 10 PDUFA

The case against leaning into MRK here is straightforward: the company heads into its 2026-10-10 PDUFA in 6 days with a setup clouded by a very recent ADC filing withdrawal, while the more constructive signals around the name sit outside the actual catalyst at hand.¹⁴⁵ That does not make MRK broken as a franchise, but it does make this specific decision date look less attractive than a simple “big pharma into catalyst” framing would suggest.¹¹⁷

The most important substrate point is the one investors cannot ignore: Daiichi and Merck withdrew an ADC filing after the FDA said they lacked the data for accelerated approval in a lung cancer population, a development captured both in sector reporting and in the monitored post stream around MRK.⁴⁵ A separate post explicitly groups the MRK/DSNKY withdrawal with other pulled U.S. oncology filings and frames the comparison as analytically meaningful, reinforcing that this was not treated as routine paperwork noise.⁷ Even if that withdrawal is not the same asset as the pending PDUFA, it still matters for how the market should discount regulatory confidence around MRK’s near-term oncology execution, especially when the event itself is close enough that positioning can easily bleed across programs.¹⁴⁷

The defense of a cautious stance is stronger because the bullish items in the substrate point to MRK’s broader pipeline quality, not necessarily to a clean readthrough for this week’s binary. One monitored post highlights placebo-adjusted HiSCR75 of 24-27% for top doses of tulisokibart at 16 weeks, with treatment-arm HiSCR75 of 40-41% versus placebo at 15%.⁶ BioSpace also described Merck’s antibody data in chronic skin disease as “highly competitive,” and another BioSpace item said BMO was the most bullish on Merck’s plans to contend with patent cliffs.¹⁹¹⁷ Those are real positives for the company’s medium-term narrative.¹⁷¹⁹ But that is exactly why they should be separated from the trading question in front of investors now: a strong platform story and encouraging non-PDUFA data do not erase the signal sent by a fresh FDA-linked withdrawal elsewhere in the portfolio.⁴⁶¹⁷¹⁹

A fair counter-argument is that MRK’s breadth is the point: one setback in an ADC filing does not define a company that continues to generate competitive immunology data and is still viewed constructively by at least some Street observers on post-LOE planning.¹⁷¹⁹ That is true as far as it goes.¹⁷¹⁹ But for a catalyst brief, the issue is not whether MRK is investable in the abstract; it is whether this is the setup to press. On that narrower question, nearby cross-currents matter. In fact, one reason the MRK withdrawal is consequential is that it appears to have improved the perceived opportunity for another featured name, with monitored posts on IDYA explicitly calling the I-DXd BLA withdrawal a positive for DLL3 ADC competitors and saying it leaves leeway in the SCLC ADC landscape.¹⁰¹¹ When a company’s own regulatory retrenchment is being read through as upside for adjacent players, that is usually not the backdrop for a high-conviction long into a deadline.¹⁰¹¹

There is also a useful contrast with JNJ, whose upcoming earnings in 9 days are supported by a pre-computed KOL tally of 4 bullish, 0 bearish, and 1 neutral, alongside posts emphasizing durability and raised forecasts for icotrokinra.^31213141516 That does not make JNJ “better” in every respect, but it underscores the central point on MRK: some catalyst setups are helped by aligned narrative momentum, while MRK’s is complicated by a recent, concrete regulatory stumble that the market is still processing.³⁴⁷ My position, then, is not that MRK lacks long-term assets; it is that this PDUFA arrives with enough portfolio-level regulatory overhang that caution is the more disciplined stance.¹⁴¹⁷¹⁹